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The tumor suppressor promyelocytic leukemia protein (PML) is located primarily in the
nucleus, where it is the scaffold component of the PML nuclear bodies (PML-NBs). PML-
NBs regulate multiple cellular functions, such as apoptosis, senescence, DNA damage
response, and resistance to viral infection. Despite its nuclear localization, a small por-
tion of PML has been identified in the cytoplasm. The cytoplasmic PML (cPML) could be
originally derived from the retention of exported nuclear PML (nPML). In addition, bona
fide cPML isoforms devoid of nuclear localization signal (NLS) have also been identified.
Recently, emerging evidence showed that cPML performs its specific cellular functions in
tumorigenesis, glycolysis, antiviral responses, laminopothies, and cell cycle regulation. In
this review, we will summarize the emerging roles of cPML in cellular functions.
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INTRODUCTION
The promyelocytic leukemia protein (PML) was initially identified
in the acute promyelocytic leukemia (APL),a disease largely associ-
ated with t(15,17) chromosomal translocation,which results in the
fusion protein of PML and the retinoic acid receptor alpha (RARα)
(de The et al., 1991; Goddard et al., 1991; Kakizuka et al., 1991; Pan-
dolfi et al., 1991). Since its discovery in the early 1990s, PML has
attracted intensive research attentions. A variety of physiological
and pathological processes has been revealed related with PML cel-
lular functions (Geoffroy and Chelbi-Alix, 2011; Carracedo et al.,
2012; Chen et al., 2012; Ito et al., 2012).
There are seven main PML isoforms (PML I–PML VIIb) as
described by Jensen et al. (2001) (Figure 1). PML I to PML VI
contain the nuclear localization signal (NLS), resulting in the PML
nuclear localization. The PML VIIb is missing the NLS and is
likely localized in the cytoplasm. Notably, PML I also contains the
nuclear export sequence (NES), which may lead to PML I local-
ization in both nuclear and cytoplasm (Figure 1). Nuclear PML
(nPML) is the central component of the sub-nuclear structure
named PML nuclear bodies (PML-NBs) and it is essential for the
formation and stability of PML-NBs, as loss of PML delocalizes the
components of PML-NBs (Zhong et al., 1999, 2000). nPML regu-
lates a variety of cellular functions including apoptosis (Guo et al.,
2000; Lin et al., 2006), senescence (Pearson et al., 2000; Vernier
et al., 2011; Martin et al., 2012), neoangiogenesis (Bernardi et al.,
2006), DNA damage response (Dellaire and Bazett-Jones, 2004;
Dellaire et al., 2006), and hematopoietic stem cell (HSC) main-
tenance (Ito et al., 2012). Despite the important role of PML in
the nucleus, PML displays both nuclear and cytoplasm localiza-
tion (Giorgi et al., 2010; Carracedo et al., 2011). In addition, the
cytoplasmic PML (cPML) splicing isoforms devoid of NLS have
been described in the cytoplasm (Jensen et al., 2001; Lin et al.,
2004; Bernardi and Pandolfi, 2007; McNally et al., 2008). The
cytoplasmic localization suggests PML may perform specific func-
tions in the cytoplasm. As expected, the cellular functions of cPML
are recently emerging and receiving great research attraction (Lin
et al., 2004; McNally et al., 2008; Giorgi et al., 2010).
cPML REGULATES TGF-β SIGNALING ACTIVATION
An unexpected study by Lin et al. (2004) demonstrated the pivotal
role of cPML in the activation of transforming growth factor β
(TGF-β) signaling. The TGF-β is a well-known tumor suppressive
factor, which induces the transcription of two cyclin inhibitors p15
and p21 and consequently causes cell growth arrest. In addition,
TGF-β stimulation can induce apoptosis and cellular senescence
(Katakura et al., 1999; Derynck et al., 2001; Siegel and Massague,
2003). Pioneering studies revealed that PML is also involved in
cell proliferation, apoptosis, and senescence. Overexpression of
PML inhibits cell growth in vitro, while Pml−/− cells grow faster
than wild-type counterparts (Mu et al., 1994; Wang et al., 1998a).
On the other hand, Pml−/− cells are resistant to multiple apop-
totic stimulations (Wang et al., 1998b). PML is also required for
oncogene induced premature aging (Ferbeyre et al., 2000; Pear-
son et al., 2000). The similarity of cellular functions indicates
that PML and TGF-β signaling might be functionally interacted.
Indeed, the TGF-β responses are dramatically impaired in Pml−/−
MEF cells (Lin et al., 2004). Surprisingly, the defects in TGF-β
responses upon PML deficiency are rescued by the restoration
of a cPML isoform (PML3 3–7), but not by a nuclear isoform
PML4 (Lin et al., 2004). Although it is of note that nPML isoforms
play a critical role in inhibiting cell growth and inducing apopto-
sis and senescence, the unexpected finding by Lin et al., suggests
the important role of cPML in the modulation of TGF-β signaling
and its cellular functions. Interestingly, TGF-β stimulation induces
the expression of cPML in the cytoplasm, strengthening their
cooperation in the cellular function regulation (Lin et al., 2004).
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FIGURE 1 | PML isoforms. There are seven main PML isoforms due to mRNA alternative splicing. PML III, PML V, and PML VI have retained intronic sequences
(indicated by *). PML I to PML VI contain nuclear localization signal (NLS). The cytoplasmic PML VIIb is devoid of NLS. Notably, PML I contains both NLS and
nuclear export sequence (NES).
Further investigation has demonstrated that cPML is required for
the TβRI/TβRII/SARA/Smad complex assembly and its localiza-
tion to the early endosome (Lin et al., 2004). Interestingly, nuclear
sequestration of cPML by TG-interacting factor (TGIF) and c-Jun
dissociates the complex formation and negatively regulates TGF-β
signaling (Seo et al., 2006), indicating that the cytoplasmic localiza-
tion is essential for cPML to activate TGF-β signaling. Consistent
with this notion, relocation of cPML from nucleus to cytoplasm
by PCTA attenuates the inhibitory effect of TGIF on the complex
formation and TGF-β signaling (Faresse et al., 2008). Moreover,
two nPML mutants devoid of their NLS localized in the cytoplasm
fully rescue TGF-β transcriptional activity similar to the cPML
isoform, further demonstrating the essential role of cytoplasmic
localization for PML to regulate TGF-β signaling (Lin et al., 2004).
Altogether, these studies demonstrate that PML cytoplasmic local-
ization is critical for TGF-β signaling. Further efforts are required
to reveal whether this phenomenon is universal for other cPML
isoforms and the nucleus-cytoplasm relocated PML isoforms.
cPML REGULATES ER CALCIUM RELEASE AND APOPTOSIS
RESPONSES
Promyelocytic leukemia protein is required for multiple apoptosis
pathways (Wang et al., 1998b). PML associated apoptosis has been
primarily attributed to nPML or PML-NBs (Guo et al., 2000; Lin
et al., 2006). PML interacts with tumor suppressor p53, recruits
p53 to PML-NBs and potentiates p53-mediated gene expression
and apoptosis (Guo et al., 2000). Two recent studies revealed that
PML-mediated apoptosis also occurs outside the nucleus. The
first study showed that cPML can be found in the early endo-
some, facilitates the assembly of the TβRI/TβRII/SARA/Smad2/3
complex and is critical for TGF-β-mediated apoptosis (Lin et al.,
2004). Recently, another study by Giorgi et al. (2010) reported the
enrichment of cPML at the endoplasmic reticulum (ER) and the
mitochondria-associated membranes (MAMs), where are the ER
and mitochondria contact sites, in primary MEFs. The MAMs
are specialized microdomains important for the Ca2+ transfer
between ER and mitochondria (Pinton et al., 2008). The Ca2+
transfer from ER to mitochondria is critical for ER stress induced
cell fate determinant. During the early phase of ER stress, Ca2+
transfer may trigger an adaptive response by promoting mito-
chondria metabolism (Bravo et al., 2011), while Ca2+ overload
in mitochondria leads to apoptotic cell death (Chami et al.,
2008). Enrichment of cPML at MAMs microdomains facilitates
the Ca2+ release from ER and consequently mediates apopto-
sis responses upon various stimuli, such as ER stress (Giorgi
et al., 2010). In line with the PML-NBs in the nucleus and the
cPML/TβRI/TβRII/SARA/Smad complex in the early endosome,
cPML also forms a large complex containing PP2A/AKT/IP3R at
MAMs to modulate the ER calcium release and apoptosis (Giorgi
et al., 2010). However, it is unclear about which isoform of PML is
enriched in the MAMs and facilitates apoptosis response. Further
examination is needed to investigate whether nucleus-cytoplasm
exported PML or bona fide cPML isoforms are involved in ER
calcium release and apoptosis.
cPML IN TUMORIGENESIS: TUMOR SUPPRESSIVE OR
ONCOGENIC?
Several lines of evidence indicate that PML is a potential tumor
suppressor. First, PML induces cell growth arrest, senescence, and
apoptosis in vitro and inhibits oncogenic transformation in vivo.
Second, PML-RARα fusion protein, an oncoprotein associated
with the occurrence of most APL cases, serves as a dominant
negative mutant to antagonize PML functions (Mu et al., 1994).
The most important evidence that attests the role of PML as
a tumor suppressor comes from the analysis of various genetic
mouse models and human cancer samples. By using Pml defi-
ciency mice as models, two studies showed that Pml deficiency
promotes chemical-induced papilloma and lymphomas develop-
ment as well as the lung cancer progression in RAS transgenic lung
tumor model (Wang et al., 1998a; Scaglioni et al., 2006). Moreover,
loss of Pml also synergizes with Pten inactivation to induce inva-
sive prostate cancer development (Trotman et al., 2006). Finally,
analysis of cancer specimens revealed that loss of PML protein
expression is frequently detected in numerous human cancers
(Gurrieri et al., 2004).
As mentioned above, cPML is essential for activation of the
tumor suppressive TGF-β signaling and consequently inhibits cell
growth, facilitates apoptosis and cell senescence (Lin et al., 2004).
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Consistently, MAMs cPML also promotes apoptosis through facil-
itating the ER calcium release (Giorgi et al., 2010). Both studies
imply that cPML may also be a tumor suppressor similar to
nPML does. Interestingly, the APL oncoprotein PML-RARα is
expressed in both nuclear and cytoplasm (Kastner et al., 1992). The
cPML-RARαdisrupts cPML-Smad2/3 interaction and antagonizes
the tumor suppressive TGF-β signaling, providing an additional
mechanism for PML-RARα oncogenic function (Lin et al., 2004).
It would be interesting to know whether PML-RARα would also
antagonize MAMs cPML functions, thereby contributing to APL
disease. Altogether, cPML likely serves as a tumor suppressor.
However, several reports on cPML mutants revealed their onco-
genic potential. The PML truncated mutant was identified in the
recurrent plasmcytoma cell cytoplasm and displayed oncogenic
role, which may be due to a dominant negative effect (Zheng et al.,
1998). More recently, two different PML mutations (1272delAG
and IVS3–1G-A) have been identified in aggressive APL patients.
Both mutations cause premature transcription stop before the NLS
domain, thereby leading to the generation of cPML mutants (Gur-
rieri, 2004). Interestingly, these cPML mutants interact with and
stabilize PML-RARα cytoplasmic complex, resulting in potentiat-
ing PML-RARα oncogenic function (Bellodi, 2006). Moreover, the
two cPML mutants can induce the relocation of nPML to cyto-
plasm and inhibits p53 tumor suppressive ability (Bellodi et al.,
2006). Altogether, these studies suggest that cPML may also be
oncogenic. Consistent with this notion, several studies showed
that cPML is upregulated in hepatocellular carcinoma (Terris et al.,
1995; Chan et al., 1998), although it is unclear whether the cPML is
derived from PML mutants, nPML relocation, or bona fide cPML
isoforms. Therefore, in addition to the cPML mutants, further
studies are needed to test whether the nucleus-cytoplasm relocated
PML and bona fide cPML isoforms bear the similar oncogenic
roles.
THE ROLE OF cPML IN METABOLISM
Deregulated energy metabolism is a hallmark of human cancers.
Aerobic glycolysis known as Warburg effect is highly utilized in
cancers and shown to be an important driving force for can-
cer progression. The M2 isoform of pyruvate kinase (PKM2)
is a glycolytic enzyme that catalyzes the dephosphorylation of
phosphoenolpyruvate (PEP) to produce pyruvate, which will be
converted into lactate rapidly. PKM2 is critical for aerobic glycol-
ysis and expressed in proliferating cells during embryogenesis and
tumorigenesis [reviewed in (Mazurek, 2011; Chaneton and Got-
tlieb, 2012)]. A recent study by Shimada et al. (2008) revealed that
cPML may be involved in glycolysis through PKM2. cPML inter-
acts with PKM2 in the cytoplasm, and the PML-2KA mutant that
contains NLS mutations and localizes in the cytoplasm inhibits
PKM2 activity and reduces lactate production (Shimada et al.,
2008). Although it is unknown about which cPML isoform indeed
interacts with PKM2 and regulates its activity, the work may pro-
vide a potential crosstalk between cPML and PKM2 in glycolysis
regulation. It will be interesting to investigate whether cPML may
participate in tumorigenesis through regulating PKM2 activity
and glycolysis.
Two recent reports revealed that PML regulates fatty acid oxida-
tion (FAO) (Carracedo et al., 2012; Ito et al., 2012). Pioneer studies
demonstrated that FAO promotes ATP generation and cancer cell
survival under metabolic stress, thus contributing to the tumor
growth and survival (Schafer et al., 2009; Zaugg et al., 2011). Inter-
estingly, loss of PML is correlated with the impairment of FAO and
ATP production (Carracedo et al., 2012; Ito et al., 2012), and its
overexpression promotes FAO, ATP generation, and cell survival
in breast cells (Carracedo et al., 2012). Collectively, these studies
suggest an unexpected survival role of PML through FAO regula-
tion. It would be interesting to characterize which PML isoform
regulates FAO and performs an unexpected tumor oncogenic role.
Further studies are needed to examine whether cPML or nPML is
involved in FAO and ATP generation.
cPML FACILITATES ANTIVIRAL RESPONSES
Interferons (IFNs) play an important role in the antiviral
responses. Upon viral infection, the cells release IFNs, which then
bind to the cell surface specific receptors and activate down-
stream signaling to combat virus infection [reviewed in (Plata-
nias, 2005)]. Interestingly, IFN treatment induces the expression
of several components of PML-NBs including SP100, NDP52,
and PML (Chelbi-Alix et al., 1995; Lavau et al., 1995) lead-
ing to increased number and size of PML-NBs. Notably, viral
infection is prone to disrupt PML-NBs and delocalizes the com-
ponents of PML-NBs (Puvion-Dutilleul et al., 1995a,b; Doucas
et al., 1996; Korioth et al., 1996; Ahn and Hayward, 1997, 2000;
Bell et al., 2000a,b). Further studies showed that the immediate-
early protein (ICPo) of the herpes simplex virus type 1 (HSV-
1) is localized to the PML-NBs and causes PML degradation
leading to the disruption of PML-NBs (Everett et al., 1998;
McNally et al., 2008). These studies imply that PML and PML-
NBs may be involved in antiviral response. The supporting evi-
dence came from a provoking study by Maroui et al. (2011).
Maroui et al., found that PML IV interacts with 3D polymerase of
encephalomyocarditis virus (EMCV) and recruits it to PML-NBs,
thus inhibiting EMCV production. Surprisingly, EMCV resistance
is specifically restricted to PML IV isoform, but not other PML
isoforms (Maroui et al., 2011). However, it is unclear whether
this PML isoform specificity also applies to other types of viral
infection.
Emerging evidence suggests that cPML is also involved in the
cellular resistance to viral infection. Studies conducted by differ-
ent groups demonstrated that PML cytoplasmic relocation can be
induced by the respiratory syncytial virus (RSV), the lymphocytic
choriomeningitis virus (LCMV) and the human immunodefi-
ciency virus type 1 (HIV-1) (Borden et al., 1998; Turelli et al., 2001;
Brasier et al., 2004). cPML cooperates with the LCMV Z protein to
inhibit eIF4E, which may reduce viral protein translation (Borden
et al., 1998; Kentsis et al., 2001). Another study by Turelli et al.
(2001) showed that cPML is implicated in HIV-1 transduction.
HIV-1 infection redistributes PML together with the integrase
interactor 1 (INI-1) from nucleus to cytoplasm, where PML and
IN1-1 colocalize with HIV-1 preintegration complex and inter-
fere with HIV-mediated transduction. The nucleus-cytoplasm
redistribution of PML and INI-1 is dependent on the exportin
(also known as Crm-1) transporting pathway. Interestingly, Crm-
1 inhibitor leptomycin B blocks the nucleus-cytoplasm export of
PML and INI-1 and increases the HIV-1 transduction (Turelli et al.,
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2001). Altogether, these reports demonstrate a crucial role of PML
cytoplasmic relocation in the antiviral responses.
As the nucleus-cytoplasm transported PML plays crucial roles
in the antiviral responses, it is not surprising that bona fide cPML
isoforms may also display antiviral activity. Indeed, a recently study
by McNally identified a novel bona fide cPML isoform (PML Ib)
in HSV-1 infected cells (McNally et al., 2008). PML Ib sequesters
the ICPo, which is involved in the viral transcription, in the cyto-
plasm, thereby repressing the viral replication. As a result, PML Ib
overexpression greatly enhances the cellular resistance to HSV-1
infection. However, the predominantly nPML I isoform does not
display antiviral ability against HSV-1. Further study showed that
the loss of PML in Pml−/− MEFs greatly enhances HSV-1 pro-
duction compared with its wild type counterparts. Remarkably,
restoration of PML Ib in Pml−/− MEFs completely rescued this
phenotype, indicating the PML Ib is sufficient for PML antivi-
ral responses against HSV-1. The elegant study by McNally et al.,
reveals a critical role of cPML Ib in antiviral responses. It remains
to be determined whether other cPML isoforms also perform
dramatic viral defense ability against HSV-1, such as the cPML
isoform involved in TGF-β signaling (Lin et al., 2004).
cPML WITH ELUSIVE CYTOPLASMIC FUNCTIONS
In addition to the aforementioned cPML, there is another por-
tion of cPML whose cytoplasmic functions still remain elusive.
The most interesting finding is that the PML-NBs is dynamically
regulated during cell cycle progress (Dellaire, 2006). PML local-
izes to the cytoplasm in mitosis phase and forms a specific complex
termed mitotic accumulation of PML proteins (MAPPs) and then
reforms PML-NBs in G1 phase. Typically, MAPPs is regarded as
the transient depot of PML-NBs dynamic regulation through cell
cycle progression (Dellaire, 2006). It will be interesting to identify
whether the MAPPs may have specific cytoplasmic functions.
The redistribution of nPML to cytoplasm has also been
described in the laminopathy diseases characterized by LMNA
gene mutations. PML cytoplasmic particles (PML-CPs) is found in
the laminopathy cells and the number of these particles increases
with disease severity (Houben et al., 2013). The PML-CPs may
come from the PML-NBs redistribution, since laminopathies
could lead to nuclear rupture. However, in the laminopathy cells
without overt abnormal nucleus, the number of PML-CPs are
also significantly increased (Houben et al., 2013), suggesting that
PML-CPs may also from in the cytoplasm. In this regard, it is
still unknown whether bona fide cPML isoforms are involved in
the formation of PML-CPs. Further research is needed to iden-
tify the origin of PML in the PML-CPs and to investigate whether
PML-CPs have direct effect to promote laminopathies.
CONCLUSION AND PERSPECTIVES
The emerging evidence we discussed in this review revealed that
cPML exhibits multiple cellular functions (Figure 2). The cPML
can be derived from nucleus-cytoplasm redistribution, bona fide
cPML isoforms or nPML mutations which lose nuclear import
ability. It is eager for the field to know whether the cellular func-
tions regulated by cPML are related to specific cPML isoforms
or nucleus-cytoplasm redistribution PML. In addition, to fur-
ther address the important role of cPML in vivo, cPML specific
animal models such as cPML knockin mice or nPML knockin
FIGURE 2 | Diverse cellular functions of cytoplasmic PML (cPML).
cPML displays both tumor suppressive and oncogenic functions.
On one hand, cPML increases TGF-β signaling or ER Ca2+ release
to suppress tumorigenesis. On the other hand, cPML inhibits
tumor suppressor p53 or potentiates oncoprotein PML-RARα to
promote tumorigenesis in acute promyelocytic leukemia (APL).
cPML may also regulate glycolysis and tumorigenesis through the
inhibition of PKM2 activity and lactate production. In addition, cPML
is involved in antiviral responses, laminopothies, and cell cycle
regulation.
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mice are needed. Another remaining question is how cPML is
regulated to orchestrate downstream events. Given that PML
undergoes distinct posttranslational modifications [reviewed in
(Carracedo et al., 2011)], it is very likely that cPML may require
certain posttranslational modifications to perform proper cellular
functions.
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